Novo Nordisk parent buys US drug firm for $16.5bn to expand Wegovy supply
Company to acquire three sites from Catalent amid runaway demand for weight-loss drug The explosion in demand for the weight loss drug Wegovy has led to the holding company behind its maker, Novo Nordisk, buying a leading US-based drugmaker for $16.5bn (£13.2bn) to increase capacity. Novo Holdings is to buy the New Jersey-based pharmaceutical firm … Read more